2025-12-03 - Analysis Report
Okay, let's analyze Recursion Pharmaceuticals Inc. (RXRX) based on the provided data.

**0) Report Overview**

This report provides a simple analysis of Recursion Pharmaceuticals Inc. (RXRX) stock performance, recent news, analyst opinions, and financial data. It compares RXRX's performance to the S&P 500 (VOO) and offers a consolidated view to aid in investment decisions.

**1) Return Rate vs. S&P 500 (VOO) Comparison**

*   **Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

*   **Return Rates:**
    *   RXRX Cumulative Return: -28.52%
    *   VOO Cumulative Return: 42.35%
    *   Divergence: -69.5 (Relative Divergence: 2.7)

*   **Analysis:** RXRX has significantly underperformed the S&P 500 (VOO).  The -69.5 divergence indicates a substantial difference in cumulative returns.  The relative divergence of 2.7 suggests the current divergence is near its historical low compared to its range.  This underperformance suggests potential concerns about RXRX's growth prospects.

*   **Alpha, Beta Analysis:**

    | Year        | CAGR  | MDD   | Alpha | Beta  | Cap(B) |
    | ----------- | ----- | ----- | ----- | ----- | ------ |
    | 2021-2023   | 22.0% | 81.0% | 26.0% | -0.2  | 5.1    |
    | 2022-2024   | 11.0% | 81.0% | -10.0% | 0.1   | 3.5    |
    | 2023-2025   | 14.0% | 80.0% | -51.0% | 0.1   | 2.3    |

    *   **CAGR:** The Compound Annual Growth Rate fluctuates, indicating inconsistent growth.
    *   **MDD:** The Maximum Drawdown is consistently high (around 80%), reflecting significant volatility and risk.
    *   **Alpha:** Alpha has decreased significantly over time, indicating a decline in relative performance compared to the market.
    *   **Beta:** Beta is relatively low (close to 0), suggesting RXRX's price movements are not strongly correlated with the overall market.
    *   **Cap:** Market Cap has decreased from 5.1 to 2.3, indicating investors have lost confidence.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 4.415
*   **Last Market Data:**
    *   Price: 4.4103
    *   Previous Close: 4.36
    *   Change: 1.15%
*   **Moving Averages:**
    *   5-day SMA: 4.431
    *   20-day SMA: 4.4772
    *   60-day SMA: 5.0808

*   **Analysis:** The stock price is currently below its 5-day, 20-day, and 60-day Simple Moving Averages (SMAs). This suggests a short-term downtrend. The recent increase in price compared to the previous close is a very small increase.

**3) Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 47.78 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.95 (Indicates potential for upward momentum)
*   **Hybrid Signal:**  "cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)" - Suggests a strong buy signal based on the MRI and other factors.
*   **Recent (20 days) Relative Divergence Change:** 1.9 (+) (Short-term increase)
*   **Expected Return (%):** -180.9 (Very Negative - Expect significant losses compared to S&P 500)

*   **Analysis:** While the MRI suggests a high investment recommendation, the very negative expected return, and the SMA trend point to caution. The RSI is neutral, suggesting neither overbought nor oversold conditions. The Recent (20 days) Relative Divergence Change indicated a short-term increase.

**4) Recent News & Significant Events**

*   **[2025-11-21] Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss:** This indicates that recent earnings were below expectations, potentially driving negative sentiment.
*   **[2025-11-07] Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates:** This suggests that after the Q3 report, the analysts are considering their estimates.
*   **[2025-11-22] Recursion (RXRX) Jumps 8% on Bargain-Hunting:** This suggests a potential rebound after a price decline, possibly due to investors seeing value at lower prices.
*   **[2025-12-01] Recursion (Nasdaq: RXRX) plans Dec. 8 webinar on TUPELO REC-4881 FAP trial readout:** A significant upcoming event (trial readout) could significantly impact the stock price.
*   **[2025-11-08] $RXRX stock fell 17% this week. Here's what we see in our data:**  Confirms a significant recent decline.
*   **[2025-11-19] Is Recursion Pharmaceuticals a Meme Stock?:**  Raises concerns about the stock's valuation being driven by social media hype rather than fundamental factors.

*   **Analysis:** The news is mixed.  The earnings miss and price decline are negative, while the bargain-hunting jump and upcoming trial readout provide some positive signals. The "meme stock" question adds an element of uncertainty.

**4-2) Analyst Opinions**

*   **Analyst Consensus:**
    *   Mean Rating: Not provided
    *   Number of Opinions: 6
    *   Target Price (avg/high/low): 6.33 / 10.00 / 3.00

*   **Analysis:**  The analyst target prices suggest potential upside from the current price, but the range is wide, indicating uncertainty among analysts.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue        |
| ---------- | ----- | -------------- |
| 2025-11-05 | -0.36 | 0.01 B$        |
| 2025-08-05 | -0.41 | 0.02 B$        |
| 2025-05-05 | -0.50 | 0.01 B$        |
| 2024-11-06 | -0.34 | 0.03 B$        |
| 2025-11-05 | -0.34 | 0.03 B$        |

*   **Analysis:**  The company is consistently losing money (negative EPS). Revenue fluctuates and is generally low. This raises concerns about the company's profitability and long-term sustainability.

**6) Financial Information**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | --------------- |
| 2025-09-30   | $0.00B    | -194.74%        |
| 2025-06-30   | $0.02B    | -5.54%          |
| 2025-03-31   | $0.01B    | -47.31%         |
| 2024-12-31   | $0.00B    | -183.62%        |
| 2024-09-30   | $0.03B    | 53.69%          |

Capital and Profitability:

| Quarter      | Equity    | ROE     |
| ------------ | --------- | ------- |
| 2025-09-30   | $1.05B    | -15.50% |
| 2025-06-30   | $0.92B    | -18.70% |
| 2025-03-31   | $0.93B    | -21.68% |
| 2024-12-31   | $1.03B    | -17.29% |
| 2024-09-30   | $0.52B    | -18.27% |

*   **Analysis:** Revenue is inconsistent and often very low. Profit margins are generally very negative, except for one quarter, indicating significant challenges in achieving profitability.  ROE is also consistently negative, suggesting the company is not effectively using equity to generate profits. Equity has been relatively stable but decreased from 2025-09-30, indicating some loss in equity over time.

**7) Comprehensive Analysis (Summary)**

RXRX has significantly underperformed the S&P 500, has shown inconsistent growth, high volatility, decreasing alpha, and declining market capitalization. Recent earnings are negative and revenue is inconsistent. Analyst target prices suggest some potential upside, but there is considerable uncertainty. Recent news highlights an earnings miss, a potential rebound, and an upcoming trial readout, but also questions about whether it is a meme stock. The Market Risk Indicator suggests high investment recommended, but the expected return is very negative, and technical indicators suggest caution.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.